Eluxadoline: Completed Phase III enrollment

Furiex completed enrollment in a 30-week, double-blind, placebo-controlled international Phase III trial evaluating 75 and 100 mg twice-daily oral eluxadoline. Furiex, which spun out of PPD LLC (Wilm...